IntelliPlex™ Lung Cancer Panel - cfRNA

The IntelliPlex™ Lung Cancer Panel comprises NSCLC driver genes' DNA mutations and RNA fusion variants detection for use with samples extracted from NSCLC formalin-fixed paraffin-embedded tissues (FFPET) or liquid biopsies such as plasma.
The cfRNA panel is a qualitative molecular assay for the detection of 28 RNA variant hotspots in ALK, ROS1, RET, NTRK1, and MET genes from plasma samples in a single well by using PlexBio's core πCode™ technology.

FEATURES

Detect 5 driver genes, 28 RNA fusion variants in one well test
Highly sensitive (10~89 copies) to detect low levels of RNA variants
Only ≥50ng RNA sample required
Time to results in <6 hours for 96 samples per run (sample preparation included)

DOWNLOAD FILE

Broad Target Coverage

Detectable 5 driver genes,
28 RNA variants in one well

Low Sample Input

Only ≥50ng RNA sample extracted from plasma required

High Sensitivity

Detects low levels of RNA variants with a high sensitivity

Quick Turnaround Time

Sample to results in <6 hours with automated reporting

Overview

Resources

Related Products

Overview

Most cases of lung cancer are sporadic, rather than hereditary, but several genes and even types of specific mutations are commonly seen in these sporadic cases. Due to the genetic diversity in lung cancers, a comprehensive and rapid test that access multiple genes' mutation profile simultaneously with a high level of accuracy, rather than individual gene testing is crucial and unmet need. Moreover, results are intended to assist clinicians in identifying patients who may benefit from available targeted treatments to achieve the personalized cancer management.

The IntelliPlex™ Lung Cancer Panel- cfRNA is an in-vitro molecular test based on πCode™technology and PlexBio's instrument platform to identify 28 RNA fusion variants in ALK, ROS1, RET, NTRK1, and MET genes in NSCLC. πCode™ technology enables the multi-variants detection in single-well with RNA samples derived from plasma. The kit provides all necessary optimized reagents for the sensitive detection of low levels of RNA variants in a background of wild-type genomic RNA by one-step RT-PCR and simultaneous PCR amplification of target cDNA. The genetic status evaluation from these NSCLC driver genes can impact the selection of and the response to targeted therapies.

Principle of πCode Multiplexing

OUR RESOURCES

IFU

Datasheet

IntelliPlex™ Lung Cancer Panel - cfRNA

Type

IFU

Publish Date

2022.05.06

BACK TO LIST